Drug information provided by: Merative, Micromedex®
Ivosidenib is used alone or together with azacitidine to treat newly-diagnosed acute myeloid leukemia (AML) in patients who are 75 years of age or older or who have health problems that prevent the use of certain cancer treatments (chemotherapy). It is also used to treat AML that has come back or has not improved after a previous treatment. Ivosidenib is also used to treat cholangiocarcinoma (bile duct cancer) that has spread or cannot be removed by surgery in patients who have already received a previous treatment. Ivosidenib is also used to treat myelodysplastic syndromes (MDS) that has come back or has not improved after a previous treatment. It is used only in patients who have an isocitrate dehydrogenase-1 (IDH1) mutation in their AML, cholangiocarcinoma, or MDS. Your doctor will test for the presence of this mutation.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: April 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?